Abstract
Inflammation is a complex pathological condition associated with exaggerated human immune system involving various activated immune cells and bio-molecules. Treatment of inflammatory diseases perticularly chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease etc. has been a big challenge for scientists as there are no safe drugs available for cure. Current therapeutic approaches to the treatment of inflammatory diseases are centered on cycloxygenase (both COX-1 and 2) proinflammatory enzymes but present available drugs of this category are associated with undesirable gastrointestinal and cardiovascular side effects. Recent scientific advents draw out the secrets of inflammation cache and understanding the involvement of several factors acting as stimulators or inhibitors thus opening new avenues for drug discoveries. Several bio-molecules such as proinflammatory cytokines, components of signal trasduction and matrix degrading enzymes resolve inflammatory responses, might be new targets for treatment of chronic inflammatory diseases. This review gathers recent advances in drug research focusing interleukin-1, TNF-α,p38 kinase, c-Jun N-terminal kinase MAP kinase, NFκB, and matrix metalloproteinases. The biological roles of these inflammatory mediators are clearly understood thus offering new targets for design of novel inhibitors for incurable inflammatory diseases. This also provides an overview of the current nonsteroidal antiinflammatory agents.
Keywords: Inflammation, IL-1, TNF-α, p38 Kinase, Matrix metalloproteinase
Current Pharmaceutical Design
Title: Novel Targets for Antiinflammatory and Antiarthritic Agents
Volume: 12 Issue: 19
Author(s): R. G. Kulkarni, G. Achaiah and G. Narahari Sastry
Affiliation:
Keywords: Inflammation, IL-1, TNF-α, p38 Kinase, Matrix metalloproteinase
Abstract: Inflammation is a complex pathological condition associated with exaggerated human immune system involving various activated immune cells and bio-molecules. Treatment of inflammatory diseases perticularly chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease etc. has been a big challenge for scientists as there are no safe drugs available for cure. Current therapeutic approaches to the treatment of inflammatory diseases are centered on cycloxygenase (both COX-1 and 2) proinflammatory enzymes but present available drugs of this category are associated with undesirable gastrointestinal and cardiovascular side effects. Recent scientific advents draw out the secrets of inflammation cache and understanding the involvement of several factors acting as stimulators or inhibitors thus opening new avenues for drug discoveries. Several bio-molecules such as proinflammatory cytokines, components of signal trasduction and matrix degrading enzymes resolve inflammatory responses, might be new targets for treatment of chronic inflammatory diseases. This review gathers recent advances in drug research focusing interleukin-1, TNF-α,p38 kinase, c-Jun N-terminal kinase MAP kinase, NFκB, and matrix metalloproteinases. The biological roles of these inflammatory mediators are clearly understood thus offering new targets for design of novel inhibitors for incurable inflammatory diseases. This also provides an overview of the current nonsteroidal antiinflammatory agents.
Export Options
About this article
Cite this article as:
Kulkarni G. R., Achaiah G. and Narahari Sastry G., Novel Targets for Antiinflammatory and Antiarthritic Agents, Current Pharmaceutical Design 2006; 12 (19) . https://dx.doi.org/10.2174/138161206777698945
DOI https://dx.doi.org/10.2174/138161206777698945 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Oxygen Therapy
Current Medicinal Chemistry 6H-Indolo[2,3-b]Quinoxalines: DNA and Protein Interacting Scaffold for Pharmacological Activities
Mini-Reviews in Medicinal Chemistry IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy FDG-PET/CT in Rheumatoid Arthritis: A Review
Current Molecular Imaging (Discontinued) subject Index To Volume 1
Current Molecular Medicine Inhibitors of Stimulator of Interferon Genes from 2019 to July 2022: An Overview of the Structure and Bioactivity
Current Drug Targets Review of Pediatric Uveitis
Current Pediatric Reviews The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases
Current Protein & Peptide Science Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Biological Evidence for the Benefit of Green Tea and EGCG in Arthritis
Current Rheumatology Reviews Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology The Role of Endostatin in Rheumatoid Arthritis
Current Rheumatology Reviews Cardiovascular Risk Prediction using JBS3 Tool: A Kerala based Study
Current Medical Imaging Integrin Antagonists: A Special Emphasis on Structural Requirements of N-benzoyl-L-biphenylalanines as α4β7 and α4β1 Antagonists
Current Signal Transduction Therapy Phosphodiesterase 7A: A New Therapeutic Target for Alleviating Chronic Inflammation?
Current Pharmaceutical Design Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets